Cargando…

Reply: Long-Term Survival and Adverse Events in Cardiac Sarcoidosis

Detalles Bibliográficos
Autores principales:	Kusano, Kengo, Ishibashi, Kohei, Yazaki, Yoshikazu, Terasaki, Fumio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627814/ https://www.ncbi.nlm.nih.gov/pubmed/36339115 http://dx.doi.org/10.1016/j.jacasi.2022.02.005

Ejemplares similares

Long-Term Survival and Adverse Events in Cardiac Sarcoidosis
por: Kupari, Markku, et al.
Publicado: (2022)

The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines
por: Terasaki, Fumio, et al.
Publicado: (2022)

Prognosis and Outcomes of Clinically Diagnosed Cardiac Sarcoidosis Without Positive Endomyocardial Biopsy Findings
por: Kusano, Kengo, et al.
Publicado: (2021)

Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J‐ACNES): A multicenter, open‐label, randomized, controlled study
por: Ishibashi, Kohei, et al.
Publicado: (2018)

Unusual Overlapping Cardiac Sarcoidosis and Long-QT Type 3 Induced Ventricular Fibrillation
por: Nishikawa, Tatsuya, et al.
Publicado: (2021)

Pathology after a combination of sequential and simultaneous unipolar radiofrequency ablation of ventricular tachycardia in a postmortem heart with cardiac sarcoidosis
por: Miyamoto, Koji, et al.
Publicado: (2018)

Reply to Yalta and Yetkin—Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Duffett, Stephen A., et al.
Publicado: (2022)

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events
por: Higgins, Angela Y, et al.
Publicado: (2016)

Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
por: Yasuda, Masakazu, et al.
Publicado: (2016)

Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis
por: Rosenthal, David G., et al.
Publicado: (2019)

Endocardial and epicardial focal activation pattern due to microreentry ventricular tachycardia in a patient with cardiac sarcoidosis
por: Kawakami, Hiroshi, et al.
Publicado: (2017)

Arrhythmia Monitoring and Outcomes in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium
por: Bressi, Edoardo, et al.
Publicado: (2022)

Clinical Features and Histopathology of Cardiac Sarcoidosis with Refractory Heart Failure: An Autopsy Case
por: Terasaki, Fumio, et al.
Publicado: (2019)

Cardiac sarcoidosis: A long term follow up study
por: Cacoub, Patrice, et al.
Publicado: (2020)

Clinical impact of increasing left ventricular pacing output in cardiac resynchronization therapy – the new optimization strategy
por: Ishibashi, Kohei, et al.
Publicado: (2016)

Comment on ‘Management of Cardiac Sarcoidosis in 2020’
por: Korovesis, Socrates, et al.
Publicado: (2021)

Multimodal approach for isolated cardiac sarcoidosis
por: Godo, Shigeo, et al.
Publicado: (2022)

The challenging diagnosis of isolated cardiac sarcoidosis
por: Kupari, Markku
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Myocardial Immunocompetent Cells and Macrophage Phenotypes as Histopathological Surrogates for Diagnosis of Cardiac Sarcoidosis in Japanese
por: Honda, Yasuyuki, et al.
Publicado: (2016)

Reply to Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns
por: Foley, K. A., et al.
Publicado: (2010)

T2-weighted short-tau-inversion-recovery imaging reflects disease activity of cardiac sarcoidosis
por: Tonegawa-Kuji, Reina, et al.
Publicado: (2021)

Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis
por: Kobayashi, Yuta, et al.
Publicado: (2021)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

Authors reply: Stevia: Long term data is lacking!
por: Purohit, Vikas, et al.
Publicado: (2018)

Implantable cardiac devices in cardiac sarcoidosis: it is about preventing the unforeseeable
por: De Bortoli, Alessandro, et al.
Publicado: (2023)

Author's reply to The Long Journey of Cardiac Lymphoma Follow-up
por: Kim, Sunhwa, et al.
Publicado: (2020)

COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
por: Bénézit, François, et al.
Publicado: (2020)

Catheter delivery system-assisted atrial lead placement in the rim of foramen ovale under transoesophageal three-dimensional echocardiography
por: Ishiwata, Mai, et al.
Publicado: (2023)

Catastrophic Events of Cardiac Sarcoidosis: A Case Report
por: Riasat, Maria, et al.
Publicado: (2022)

Prognostic Implication of the Resolution of Myocardial FDG Uptake in Patients With Cardiac Sarcoidosis
por: Okabe, Toshitaka, et al.
Publicado: (2023)

Earlier Right Ventricular Pacing in Cardiac Resynchronization Therapy for a Patient with Right Axis Deviation
por: Hattori, Yusuke, et al.
Publicado: (2017)

Reply: Cisplatin-Associated Aortic Thrombosis: A Review of Cases Reported to the FDA Adverse Event Reporting System
por: Cameron, Alan C., et al.
Publicado: (2021)

Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Yalta, Kenan, et al.
Publicado: (2022)

Insufficient evaluation of adverse events is not a proof of safety. Reply to LG Hemkens, U Grouven, R Bender, et al. [letter]
por: Home, P. D., et al.
Publicado: (2010)

Response to: implantable cardiac devices in cardiac sarcoidosis—it’s about preventing the unforeseeable
por: Park, Innu, et al.
Publicado: (2023)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Depicting adverse events in cardiac theatre: the preliminary conception of the RECORD model
por: Parissis, Haralabos, et al.
Publicado: (2013)

Reply to “Tachycardia, adverse effect, COVID-19 vaccine”
por: Teresa Marco García, M., et al.
Publicado: (2023)

Adverse events during short- and long-term exposure to low-dose weekly methotrexate for rheumatic diseases
por: Garton, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nk6mm4lb3i691i3vklk6guvj8q